12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Actelion sales and marketing update

Actelion launched 0.016% Valchlor mechlorethamine in the U.S. to treat stage IA and IB mycosis fungoides, a type of cutaneous T cell...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >